Non-Hodgkin Lymphoma Diagnostics Market By Type (Lymph Node Biopsy (Immunophenotyping, Cytogenetic Analysis, Gene Expression Profiling, Microarray analysis), (Physical Imaging (MRI Scanning, CT-Scan, X-rays, Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), Blood Tests)), By Type of NHL (B-Cell Non-Hodgkin Lymphoma (Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma, Mantel Cell Lymphoma, Primary Central Nervous System Lymphoma), (T-Cell Non-Hodgkin Lymphoma (Peripheral T-Cell Lymphoma not Otherwise Specified, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Adult T-Cell Lymphoma, Nasal type NK/T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma), By Category of Condition (Category A, Category B, Category X, Category E), By End User (Hospitals, Diagnostic Centers, Clinics), and Geography.  

Non-Hodgkin Lymphoma Diagnostics Market size was valued at USD 12149.12 million in 2021 and is expected to grow at a CAGR of 10.8% from 2022-2028. Several factors, such as AIDS infection, immunosuppressive medications, occupational exposures, pesticide proximity, and smoking, are key risk factors for the development of NHL. With around 4% of all cancer cases in the US, non-Hodgkin lymphoma (NHL) is one of the most prevalent tumours. According to the American Cancer Society, there will be an estimated, NHL will be identified in about 80,470 persons (44,120 men and 36,350 women). Adults and children are both included in this. Non-Hodgkin lymphoma is the second most frequent cancer in people with HIV, and some people with AIDS also have lymphoma. It is true that non-Hodgkin lymphoma patients should routinely undergo HIV and hepatitis virus screenings. A thorough assessment of the burden brought on by malignancies was made by the Global Burden of Disease study (GBDs), which made it easier to monitor the temporal patterns in the disease burden. The idea that there is a connection between obesity and NHL has been supported by concurrent rises in the prevalence of obesity and the incidence of NHL during the past few decades. The prognosis for those who have non-lymphoma Hodgkin's has improved as a result of improvements in diagnosis and therapy. Researchers are investigating ways to avoid infections such HHV-8, HIV, HTLV-1, and H. pylori that have been linked to non-Hodgkin lymphoma. The chance of getting non-Hodgkin lymphoma may be decreased by avoiding exposure to certain substances, such as lead, arsenic, pesticides, vinyl chloride, and asbestos.

Recent Market Developments:
In May 2021, PerkinElmer, Inc. purchased Immunodiagnostic Systems Holdings PLC in order to grow its overall diagnostics business for about $155 million.